Hematology News

Anemia independently correlated with lower eGFR and an increased risk of end-stage kidney disease, cardiovascular disease, coronary heart disease, stroke, heart failure and death, according to recently published data.

Despite the severe pain and mortality risk associated with sickle cell anemia, few children undergo the recommended screening and treatment for this condition and its complications, according to a CDC report.

In a retrospective study of more than 10,000 bloodstream infections, a delay of 12 hours in initiating appropriate antimicrobial therapy was associated with increased 30-day mortality, but shorter delays were not, researchers found.

Use of combined oral contraceptives in women with obesity may confer elevated CV risk in the form of venous and arterial thromboembolism, researchers reported.

Anthos Therapeutics announced abelacimab, a fully human monoclonal antibody inhibiting factor XI, received fast track designation from the FDA for an indication to prevent stroke and systemic embolism in patients with atrial fibrillation.

Two-thirds of women of child-bearing age who began taking anticoagulants for acute venous thromboembolism had abnormally heavy menstrual bleeding in the months that followed therapy initiation, according to data from a prospective study.

The FDA granted priority review to efanesoctocog alfa as prophylactic treatment for patients with hemophilia A.

Anticoagulation and antiplatelet therapy can reduce risk for venous thromboembolism in COVID-19; however, research suggests these treatments may not influence risk for mortality, speakers reported.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 10-13 in New Orleans.

Merck announced its investigational factor XI inhibitor to reduce risk for major thrombotic CV events in patients with end-stage renal disease has received fast track designation from the FDA.